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1. Introduction 
“Electrical storm” (ES) has been adopted as the term used to describe a period of cardiac 
electrical instability manifested by recurrent malignant ventricular arrhythmias. The definition 
of ES and the clinical implications of an episode have evolved as our armamentarium of 
pharmacologic, device –based and interventional anti-arrhythmic therapies has broadened. 
Prior to the widespread use of implantable cardioverter defibrillators (ICDs), the most 
commonly accepted definition of arrhythmia storm or electrical storm was “recurrent 
hemodynamically destabilizing ventricular tachycardia or ventricular fibrillation occurring 
two or more times in a 24-hour period, and usually requiring electrical cardioversion or 
defibrillation”. 1-8 An episode of electrical storm carried serious clinical consequences with an 
in-hospital mortality rate of up to 14% during the first 48 hours.3,6,7. The mortality rate for an 
out-of hospital episode of electrical storm can only be speculated but would of course be 
similar to the 80-90% mortality rate of an out of hospital cardiac arrest7-9. 
Because ICDs often terminate potentially life threatening ventricular arrhythmias before any 
signs or symptoms of hemodynamic instability develop, the definition of ES has been 
modified and continues to be the subject of debate 12,8,-13. Currently, the most widely 
accepted definition of ES in the literature and clinical practice is the occurrence of ≥ 3 
distinct episodes of ventricular tachycardia (VT) and/or ventricular fibrillation (VF) within 
a 24-hour period resulting in device intervention (anti-tachycardia pacing [ATP] and/or 
shock delivery)1,2,6,8,11-15. To qualify as electrical storm, the three episodes of ventricular 
tachycardia or ventricular fibrillation cannot be continuous VT/VF in which device therapy 
is unsuccessful. Some authors have assigned an arbitrary time interval, generally 5-minutes 
between VT/VF episodes, as requisite in the definition of electrical storm11-15. Others have 
stated that incessant ventricular tachycardia or fibrillation, in which device therapy results 
in the return of even one beat of native rhythm should be included in the scope of ES, 
representing the most serious form of ES 1,2,8,11-15.  
2. Incidence and timing of ES 
The majority of data regarding the incidence, timing and prognosis of electrical storm comes 
from patients who have undergone ICD implantation for secondary prevention of cardiac 
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arrest (table 1). Lack of a consensus definition for ES, as well as differences in ICD implant 
indications, concomitant medical therapy, and follow-up periods all contribute to the 
disparate reported incidence rates of 10-60% in the secondary prevention population. Using 
the definition of >/= 3 VF/VT episodes in 24-hours requiring device intervention, the 
incidence of ES is approximately 10-28% over a 1-3 year follow-up period when ICDs are 
placed for secondary prevention of cardiac arrest1,2,8,10-21. From a more consistent study 
population in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II), the 
reported incidence of electrical storm in a primary prevention ICD population is 
substantially lower at 4%13.  
 
Author Definition Incidence Prognosis 
Fries22 ≥ 2 VT w/ 1 hr SR 60%, (34/57)  ↑ in mortality over mean follow up 3y, 26% 
with ES vs 4% without ES (P < .05) 
Credner6 ≥ 3 VT/24 hr 10%, (14/136) No ↑ in mortality 
Greene17 ≥ 3 VT/24 hr 18%, (40/227) No ↑ in mortality 
Bansch15 ≥ 3 VT/24 hr 28%, (30/106) RR 2.17 for mortality (CI 1.35 -3.48, P = .031) 
Exner12* ≥ 3 VT/24 hr 20%, (90/457) RR 2.4 for mortality (CI 1.3 -4.2, P = .03) 
Verma20 ≥ 2 VT/24 hr 10%, (208/2028) ↑ in mortality (P = .001, RR not listed) 
Stuber16 ≥ 3 VT/2 weeks 24%, (51/214) 5-y survival of 67% with ES vs 91% without 
ES (P=.0007) 
Gatzoulis14 ≥ 3 VT/24 hr 19%, (32/169) RR 2.13 for mortality (CI 1.07 - 4.24,  
P = .031) 
Hohnloser18 ≥ 3 VT/ 24 hr 23%, (148/633) No ↑ in mortality 
Arya19 ≥ 3 VT/ 24 hr 14%, (22/162) N/A 
Brigadeau21 ≥ 2 Sep VT/24 hr 40%, (123/307) No ↑ in mortality 
Sesselberg13† ≥ 3 VT/ 24 hr 4%, (27/719)  RR 7.4 for mortality (CI 3.8 -14.4, P<.01) 
*Secondary prevention population – AVID trial.  
†Primary prevention population – MADIT II.  
SR, sinus rhythm; VT, ventricular tachycardia; hr, hour; Sep, separate; RR, relative risk; CI, confidence 
interval 
Table 1. Incidence and Prognosis of Electrical Storm. 
The time from ICD implant to first episode of electrical storm varies among published 
reports. This heterogeneity of timing likely stems from differing device indications, cardiac 
substrate, and adjuvant medical therapy. In the series by Credner et al among patients 
whose ICDs were implanted for secondary prevention, 10% experienced electrical storm at a 
mean follow-up time of 4.4+/-4.5 months. This is the earliest reported time period from ICD 
implant to ES, but was similar to that of ICD implant to first appropriate device therapy of 
4.1+/-4.8 months in this series6. Among 457 patients who received an ICD with advanced 
storage capability in the secondary prevention trial Antiarrhythmics Versus Implantable 
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Defibrillators (AVID), the incidence of storm was 20% with the initial episode occurring 
9.2+/-11.5 months after ICD implantation12. A sub-study of the MADIT II trial, which 
represents the largest database to analyze ES in a primary prevention population, reported a 
4% incidence of ES at a mean time of 11.1+/-9.4 months13.  
Frequent episodes of ventricular tachycardia can occur in the peri-operative period 
following ICD implantation. This was seen more commonly with open thoracotomy 
placement of epicardial patch electrodes than with newer transvenous ICD systems. The 
etiology of this peri-operative electrical instability is likely myocardial inflammation and 
treatment with standard anti-arrhythmic therapy is often ineffective22-24. An early increase in 
the incidence of ventricular arrhythmias has been reported in some patients with cardiac 
resynchronization devices. The mechanisms are as yet unclear but have been speculated to 
be related to increased dispersion of repolarization as well as gradients of concealment from 
differential ventricular pacing.25-26  
3. Causes/triggers and risk factors for electrical storm 
Among published reports an acute cause or trigger for electrical storm was identified in the 
minority of episodes. Even an exhaustive search for an acute cause may prove fruitless in up 
to 80% of patients.1-3 The Shock Inhibition Evaluation with Azimilide (SHIELD) trial 
assessed the effects of azimilide on the frequency of device therapies in ICD patients. A 
precipitating cause for ES was found in only 13% (19/148) of storm patients in the SHIELD 
trial. The causes for ES were new or worsened congestive heart failure in 9% (13/148) and 
electrolyte disturbances in 4% (6/148)18. The usual suspect factors for precipitation of 
arrhythmias, such as electrolyte imbalance, ischemia, congestive heart failure (CHF) 
exacerbation and medication noncompliance, etc. have been reported with variable 
frequencies.1,2,6,12-18 In a restropective review of 40 secondary prevention patients with a total 
of 61 electrical storms, Greene et al. reported no identifiable cause in 29%, new or worsened 
CHF in 15%, medication non-compliance or adjustment of antiarrhythmic medication in 
20%, psychological stress in 10%, post-ICD placement in 13% and excess alcohol use in 8%.18 
The reported 70% identification of an acute cause in this series is disparate from the larger 
published trials but does point out the need to take a thorough history when presented with 
a storm patients to effectively treat the current storm episode and prevent further ES.  
Of equal importance to recognizing acute precipitants of storm is identifying factors that 
would increase the risks for developing repetitive malignant arrhythmias in ICD patients. 
Secondary analysis of the MADIT II trial revealed that patients who had post-enrollment 
coronary events (myocardial infarction or angina) were 3.1 times more likely to experience 
electrical storm.13 In fact, 7 (26%) of 27 patients with ES suffered an ischemic event within 4 
weeks of their initial storm episode. Renal insufficiency was associated with a 2.1-fold 
increase in risk for electrical storm in the primary prevention MADIT II trial and has been 
associated with increased risk in secondary prevention populations13,21 The clinical variable 
most strongly associated with development of ES among MADIT II patients was an interim 
post-enrollment arrhythmic event in the form of isolated ventricular tachycardia or 
ventricular fibrillation. Of the patients who experienced electrical storm during follow-up, 
52% of them had a prior isolated arrhythmic event. These patients were 9.1 times more 
likely to experience electrical storm than patients without these isolated tachyarrhythmias.13 
Although interim hospitalization for congestive heart failure was predictive of appropriate 
device therapy for VT/VF in the MADIT II trial, it was not predictive of electrical storm.13,27 
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Data investigating acute causes of and risk factors for development of ES have often 
grouped together diverse patient populations with an array of cardiovascular substrates, 
degrees of CHF, revascularization status, ischemic burden, medical therapy and so on. 
Because of this, the literature to date is far from comprehensive or conclusive, but does 
imply that storm is the result of a complex interplay between a predisposing 
electrophysiological substrate and acute alterations in autonomic tone and cellular milieu. 
Dynamic progression of the underlying myocardial substrate through progressive tissue 
fibrosis, ischemia and/or ventricular remodeling can manifest as an isolated 
tachyarrhythmic episode heralding future electrical storm. The critical role of increased 
sympathetic activity in precipitating storm is substantiated by the temporal relation to 
worsening CHF, concurrent medical illness and emotional stress. 1,2,6,8,11-13,. 
4. Arrhythmias and ICD therapies during electrical storm 
The majority of storm episodes (86-97%) are caused by monomorphic ventricular 
tachycardia. VF alone accounts for 1%-21% of ES, mixed VT/VF 3%-14% and polymorphic 
VT 2-8%.1,2,6,8-21 As illustrated in table 2, there is an extremely variable distribution in the 
number of tachycardias per episode of storm, as well as the number and types of therapies  
 
StudyA ES Arrhythmias No. of VT/VF episodes 
per ES
ES Therapies 
Fries22 Majority VT, percentages 
not listed 
NA 43% with ATP only, 25% ATP 
and shock, 23% shock only 
Credner6 64% VT, 21% VF, 14% 
VT+VF 
Mean = 17 ± 17 (range, 3 
to 50)  
NA 
Greene17 97% VT, 3% pVT Mean = 55 ± 90 (range, 4 
to 465) 
23% with ATP only, 77% ICD 
shock ± ATP 
Bansch15 86% VT, 8% pVT/VF, 4% 
VTs with various morph. 
Median = 19 (range, to 
440) 
NA 
Exner12 I86% VT, 14% VF or 
VT+VF 
Median = 4 (range, 3 to 
14) 
46% shocks only, 28% ATP only, 
26% shocks and ATP 
Verma20 52% VT, 48% VF NA 5 ± 5 shocks 
Stuber16 93% VT, 7% pVT Median = 8 (range, 3 to 
1200) 
31% ICD shock only, 19% ATP 
followed by shock, 50% ATP 
only 
Gatzoulis14 NA NA ATP 21 ± 33 per ES episode 
Shocks 8 ± 4 per ES episode 
Hohnloser18 91% VT, 8% VT+VF, 1% 
VF  
Median =5 (range, 3 to 
11) 
7% ICD shock only, 70% ATP 
only, 23% shocks and ATP 
Brigadeau21 90% VT, 8% VF, 2% pVT Range = 2 to > 15 18% shocks only, 26% ATP only, 
56% shocks and ATP 
Sesselberg13 78% VT, 22% VF NA NA 
VT, ventricular tachycardia; pVT, polymorphic ventricular tachycardia; VF, ventricular fibrillation; 
ATP, anti-tachycardia pacing  
Table 2. Arrhythmias and Therapies During Episodes of Electrical Storm. 
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delivered. The clinical presentation of storm can range from repetitive hemodynamically 
destabilizing episodes of VT/VF requiring multiple ICD shocks to asymptomatic 
tachycardias that are treated by ATP and discovered retrospectively through outpatient ICD 
interrogation. Whether patient outcomes are influenced by the clinical manifestations and 
therapies delivered during an episode of storm is unknown.1,2,6,8-21  
Verma et al20 , reported a significant correlation between the initial arrhythmia that led to 
ICD implantation and the arrhythmia responsible for ES. Among patients whose ICDs were 
placed for prior VT, 64% of ES episodes were caused by VT compared to only 28% by VF. 
For those patients whose ICDs were placed for prior VF, 45% of ES episodes were caused by 
VF and only 14% by VT.20 Analysis of MADIT II patients with electrical storm revealed 
similar findings. Of 12 patients who had a prior episode of VT, 11 subsequently had VT as 
their initial rhythm in their ES. Patients with a prior isolated episode of VF also had this 
rhythm as their initial rhythm in the first ES.13,20 The predilection for patients with coronary 
artery disease (CAD) and previous VT to have storm caused by monomophic VT, taken 
together with the influence of storm on future survival (discussed later), raises the question 
as to whether medical therapy alone is an aggressive enough strategy for prevention of ES in 
patients with ischemic cardiomyopathy who experience appropriate ICD therapies for VT. 
Whether or not more definitive substrate modification with re-vascularization or catheter 
ablation of VT in select patients may prove an effective means of reducing long-term 
morbidity and mortality in patients with a history of ES or those at significant risk for future 
storm awaits further data specifically addressing this topic.  
5. Prognosis and clinical implications of ES 
While we appear to have adequate pharmacologic and non-pharmacologic measures to help 
bring an end to the series of arrhythmic events, the mortality associated with these electrical 
storms is nevertheless very high in carefully analyzed data that include larger numbers of 
patients with sufficient follow-up. In the AVID trial12, 34 (38%) of the 90 patients with ES 
died during follow-up, compared to 15% of those with VT/VF in the absence of ES, and 22% 
among the remaining patients. Electrical storm was independently associated with a 2.4-fold 
increase in the risk of death overall (figure 1). Many of the deaths occurred early with a 
mortality risk that was 5.4-fold higher during the first 3-months following ES (figure 2). 12 
Among patients who received an ICD for primary prevention reasons in MADIT II, those 
with electrical storm had a 7.4 fold higher risk of death compared to those without treated 
arrhythmias (figure 1). Once again, early mortality post ES was very prominent, with a 17.8 
fold increased risk of death during the first 3 months. Although mortality risk persisted after 
the initial storm event, this risk was somewhat attenuated, with a relative risk of 3.5 after 3 
months (figure 2).13 Differing from AVID, patients in MADIT II with isolated VT/VF 
episodes were also at an increased risk of dying with a hazard ratio of 2.5.12,13 However, 
patients in MADIT II with ES still had 2.9 fold increased risk of death when compared to 
those with VT/VF in the absence of ES. Once a patient had a storm event, the mode of death 
differed from those patients with isolated VT/VF or no arrhythmic events. The rate of non-
sudden cardiac death was significantly higher for those with ES (23%) compared to those 
with isolated VT/VF (8%) and no recorded ventricular arrhythmia (5%). Storm patients 
were more likely to suffer an ischemic-mediated event (myocardial infarction or angina) as 
compared to patients without ES. Finally, once storm occurred, the incidence of a recurrent 
storm episode was 2.3%, 4.7% and 6.2% for years 1, 2 and 3, respectively.13  
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Electrical Storm
Prognosis/Mortality
 AVID (RR 2.4, 1.3-4.2)
 MADIT II (RR 7.4, 3.8-14.4)
Exner DV Circulation 2001;103: 2066-2071
Sesselberg HW Heart Rhythm;2007;4: 1395-1402
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p = 0.003
p < 0.01
RR (95% CI)
 
Fig. 1. 
 
AVID RR (95% CI) p
< 3 mo. post storm 5.4 (2.4-12.4) 0.0001
> 3 mo. post storm 1.9 (1.0-3.5) 0.04
MADIT II RR (95% CI) p
< 3 mo. post storm 17.8 (8-39.5) <0.01
> 3 mo. post storm 3.5 (1.2-9.8) 0.02
Exner DV Circulation 2001;103: 2066-2071 
Sesselberg HW Heart Rhythm;2007;4: 1395-1402
Electrical Storm
Early vs. Late Mortality Risks
 
Fig. 2. 
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Analysis of these larger trials consistently indicates that in both populations of primary and 
secondary prevention indications for ICD implant, ES presages mortality, mostly due to 
non-sudden cardiac causes.12,13 It is clear that the very immediate mortality associated with 
ES is not high suggesting that the acute management strategies are relatively 
successful.1,2,7,11-21 However, the subsequent mortality is very high and often due to non-
arrhythmic causes.11-13 The initial few months following an episode of electrical storm 
appear to be a critical window for close monitoring and therapeutic intervention targeting 
not only the potential arrhythmic causes, but all cardiac issues.12,13 Whether it is the 
progressive worsening of the substrate or the additive adverse effects of the armada of 
medical therapy that these patients are placed on (more likely a combination of these) that is 
the culprit for the substantially higher mortality is unclear.  
The role of the shocks themselves as contributing to myocardial injury and inflammation or 
even remodeling should not be overlooked. Patients who receive multiple ICD shocks can 
have detectable troponin elevations consistent with myocardial injury.1,2,,12, 28,29 Pathological 
changes including contraction band necrosis, vacuolar cytoplasmic clearing and myocyte 
loss have been visualized on myocardium under patch electrodes in patients who have 
experienced multiple defibrillations.29-31 Myocardial injury or stunning from recurrent 
defibrillations may activate the neurohormonal cascade responsible for worsening heart 
failure and ultimately cardiovascular mortality. 1-2,7,11,27, 31-34  
6. Treatment of ES 
The treatment of electrical storm entails:  
i. Promptly identifying and treating precipitating causes or triggers such as drug 
toxicities, electrolyte imbalance or acute myocardial ischemia.1-2,35 
ii.  Attempting to understand the underlying cardiovascular substrate for incessant 
ventricular arrhythmias (ischemia, decompensated heart failure, pause dependent 
polymorphic VT, etc.).1,2,35 
iii. Suppressing the ventricular arrhythmias via pharmacologic, device related or 
interventional mechanisms.1,2,35 
iv. Establishing a therapeutic regimen with frequent follow-up visits in an effort prevent 
further ES and mortality in the early vulnerable period.1-2 
Electrical storm can be a highly-charged clinical situation associated with significant patient 
anxiety and discomfort, which further elevates sympathetic tone, and leads to an even 
greater propensity for ventricular arrhythmias.1-4 The cornerstone of immediate therapy is 
sympathetic blockade accomplished by the use of intravenous (IV) beta-blocking agents 
combined with sedatives, usually benzodiazepines.1-4,7, 22, 35 A beta-one selective agent is 
often used first, but if ineffective, a nonselective beta-blocker such as propanolol can be 
substituted. 1,2,35-37 For highly symptomatic patients, intubation and anesthesia may be 
necessary and even therapeutic.1-2,38-39 Successful sympathetic manipulation via left stellate 
ganglionic blockade has been reported in post-myocardial infarction (MI) patients with 
electrical storm. 40 
In patients with ICDs, device reprogramming may be necessary. Overdrive pacing by 
increasing the lower rate limit of the ICD may be effective in preventing further electrical 
storm, particularly when ventricular arrhythmias are pause-dependent or involves tissue 
automaticity.1,7,14 While the addition of anti-tachycardia pacing (ATP) will not eliminate the 
VT trigger, a significant percentage of monomorphic VT can be successfully terminated by 
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ATP, reducing the anxiety, discomfort and increased sympathetic tone associated with 
recurrent ICD shocks.1-2,41 For patients with single chamber defibrillators, consideration can 
be given to addition of an atrial lead or even upgrade to cardiac resynchronization therapy. 
These modifications may allow for up-titration of heart failure and anti-arrhythmic therapy. 
As will be discussed later, in appropriately selected patients, cardiac resynchronization 
therapy (CRT) with a bi-ventricular implantable cardioverter defibrillator (CRT-D) may 
reduce the incidence of electrical storm.42 
The instinct to push anti-arrhythmic agents must be restrained, because with the exception 
of amiodarone, there is little evidence of benefit and the potential for pro-arrhythmia.1-,4,7,35 
In the absence of significant electrolyte imbalance or drug-induced prolonged QT syndrome 
with polymorphic VT, amiodarone is often the anti-arrhythmic agent of choice for treatment 
of ES, with demonstrated benefit in multiple clinical studies.2,4,6 The efficacy of intravenous 
amiodarone in ICD patients with storm is also supported by case series.14,17 If the 
combination of intravenous amiodarone and beta-blockers does not suppress ES, the 
addition of lidocaine is sensible.1,2,14 Certain clinical entities such as electrical storm in the 
setting of Brugada syndrome are often heart rate sensitive and can be suppressed by using 
isoproterenol to increase the sinus rate. Isoproterenol infusion has also been used to 
suppress the VF triggers during electrical storm in patients with Idiopathic VF. 43-44 
Once a patient’s arrhythmias have been suppressed, the focus should shift towards 
evaluation for and treatment of changes in the underlying cardiovascular substrate such as 
worsening ischemia or heart failure and reduction in left ventricular ejection fraction 
(LVEF).1,2,8,12 Larger scale trials have demonstrated that the first few months, post-ES are a 
critical window for intervention.1-2,12-13 Diligent implementation and augmentation of 
therapies with proven mortality benefit in similar patient populations is mandatory. 
Standard heart failure therapy, particularly beta-blockers should be maximized. 
Revascularization clearly has a role in preventing sudden cardiac death and reducing the 
ability to induce ventricular fibrillation and polymorphic ventricular tachycardia. Patients 
with inducible or spontaneous monomorphic VT do not respond as well to 
revascularization, likely due to a more scar based substrate rather than direct membrane or 
channel instability.45-46 For these patients, aggressive anti-tachycardia pacing should be 
utilized in an effort to reduce shock burden in the VT zone.1,2,8,41 The relative benefits and 
risks of long-term anti-arrhythmic therapy versus catheter ablation of ventricular 
tachycardia must be weighed. The recently released Substrate Mapping & Ablation in Sinus 
Rhythm to Halt Ventricular Tachycardia (SMASH-VT) study showed promising results for 
the ability of substrate mapping to reduce ICD therapy in patients with ischemic 
cardiomyopathy.47 However, success rates for catheter ablation for VT can vary based on the 
substrate and the experience of operators which are factors that need to be taken into 
consideration (some are difficult to control for). As this promising therapy evolves, it will 
likely be utilized earlier in the clinical course for patients who receive appropriate ICD 
therapy. 47-49  
7. Cardiac resynchronization therapy and ES events 
Cardiac resynchronization therapy has been reported to halt ES events in some patients and 
yet it has also been reported to induce ES in others. In patients who present with ES, cardiac 
resynchronization therapy in a qualified patient, i.e., widened QRS duration, advanced 
heart failure and depressed left ventricular function, has been shown to resolve the 
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arrhythmic events.50-52 Paradoxically, there also has been several case reports of ventricular 
arrhythmia storm post cardiac resynchronization therapy, either de novo implants or 
upgrades.53-55 The mechanism of arrhythmia storm has been speculated to be related to the 
heterogeneous transmural repolarization across the ventricle56 and possible concealment 
related to left or bi-ventricular pacing. The programmed pacing from the left ventricular 
lead of the resynchronization device has been reported to reinitate reentrant ventricular 
tachyarrhythmias by concealment into a potential VT circuit antidromically setting up 
conditions allowing for propagation of the wavefront orthodromically within the VT 
circuit.57 
It appears that there are specific subsets of patients whose myocardial substrates are more 
susceptible to proarrhythmic effects related to biventricular pacing. Possibly, premature 
ventricular contractions (PVC’s) that occur during or with biventricular pacing may alter the 
conduction characteristics and/or the repolarization process sufficiently to set up conditions 
such as concealment that create sufficient ventricular heterogeneity for arrhythmogenesis. 
Particular risk factors for these events are as yet unclear and further work is needed for 
further elucidation. In these patients, it is worthwhile programming the left ventricular 
pacing off, even if the patient may be pacing dependent. Further intervention can be 
pursued, whether pharmacologically or non-pharmacologically to modify the substrate. 
Care providers should also be mindful that the implanted lead(s) may be the culprit serving 
as the origin for arrhythmia and lead extraction/revision will need to be considered in these 
cases.  
Retrospective data have suggested in a non-randomized population, cardiac 
resynchronization therapy does not actually result in an overall higher incidence of 
ventricular arrhythmia storm.58 These data have limited validity due to it nature of 
uncontrolled population and varied underlying pathology. The availability of more robust 
data from randomized clinical trials will be better equipped to address whether or not 
cardiac resynchronization therapy is actually related to an increased incidence of ventricular 
arrhythmia storm. The Multicenter Automatic Defibrillator Implantation Trial-Cardiac 
Resynchronization Therapy (MADIT-CRT) randomized patients with mild congestive heart 
failure (NYHA Class I-II), LVEF <30% and widened QRS duration (>130 msec) to either 
CRT-D or non-resynchronization ICD device implants. The results from this prospectively 
randomized trial have not detected an overall proarrhythmic effect related to CRT therapy 
vs. ICD.59 In fact, these results reveal patients who are responders to CRT, i.e. patient with 
improved heart failure status and echocardiographic parameters, experienced a lower 
incidence of ventricular tachyarrhythmia overall.60  
8. Ablation therapy for ES events 
When electrical storm is persistent or even refractory to drug therapy, catheter ablation 
should be pursued as appropriate. Ablation strategies utilizing entrainment mapping to 
identify critical isthmus as well as scar substrate modification have been demonstrated to be 
effective in reducing arrhythmic events acutely and chronically. Catheter ablation was 
utilized as an urgent treatment strategy in a study comprising of 95 consecutive patients 
who presented with recurrent or incessant ventricular arrhythmia and ICD shocks. The 
patients were already on aggressive antiarrhythmic medical therapy, including 94% on 
amiodarone. Successful ablation of the ventricular arrhythmia, defined as suppression of 
any further inducible VT, was achieved in 68 of the 95 patients after more than one ablation 
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procedure. At a median follow-up of 22 months, none of these patients had further ES, and 
the mortality rate was 9%. In contrast, failure to suppress the clinical VT occurred in 10 of 95 
patients and was associated with recurrent ES in all and a 40% rate of cardiac mortality.61 
Catheter ablation success is often defined by the underlying arrhythmic substrate. Catheter 
ablation may also be effective in reducing drug refractory ES episodes in which VF was 
repeatedly precipitated by ventricular premature contractions originating from either the 
left or the right ventricle.62 However the data for this is not as abundant as the strategy of 
circuit mapping and elimination of reentrant pathways.  
There is now accumulating data that suggest earlier intervention may lead to a higher 
degree of success. SMASH-VT47 and the Ventricular Tachycardia Ablation in Addition to 
Implantable Defibrillators in Coronary Heart Disease (VTACH) trial63 have shown that 
early intervention even prior to any clinical ICD appropriate VT therapy can be delayed 
with successful VT substrate modification by ablation. In a recent study comparing the 
outcome of patients undergoing VT ablation, a group of patients receiving more 
appropriate ICD therapy and higher doses of amiodarone prior to successful ablation had 
a higher risk of further ICD therapy and a need to continue more aggressive medical 
therapy, as compared with those with less ICD shocks and lower doses of amiodarone 
needed prior to referral for ablation.64 Furthermore, there was also a more favorable short-
term (1 year) VT-free survival rate in the group being referred for catheter ablation with 
less advanced arrhythmic conditions. This study included some patients with ES but not 
all presented with ES. 
Elimination of critical isthmuses of most or all potential circuits appears to be important in 
the suppression of continually inducible ventricular tachycardia and associated with 
improved patient outcome. This in turn, would logically be related to the extent of 
underlying myocardial disease. Therefore, the success of the ablation may be, at least in 
part, linked to the degree of myocardial scarring contributing to the arrhythmic substrate 
and beyond the technical and knowledge limitations of current ablation procedures. This 
again stresses the importance of early intervention where the acute success rates for ablation 
and short-term outcome may be higher. Catheter ablation holds the promise of successful 
substrate modification in the high-risk patients with ES with short-term outcome in 
reducing the rates of VT and ICD therapy and yet, data demonstrating an improved patient 
survival in any randomized fashion is still lacking.65 
9. Conclusions and future directions 
Electrical storm is now a well recognized clinical entity among patients with ICDs. 
Hopefully with more data based on less heterogeneous ICD populations and with 
continuing careful scrutiny, we may better understand the precipitating causes and 
exacerbating factors that lead to these malignant ventricular storms. Of additional 
importance is that we continue to explore the nature of ICD device programming and the 
interaction between the type of ICD therapy delivered and future prognosis. Recent data 
gathered from large ICD populations suggests that the type of therapy delivered ATP vs. 
ICD shocks may influence future mortality.66,67 While the occurrence of an electrical storm 
episode may indicate a changing or worsening cardiovascular substrate, the addition of 
multiple shock therapies to an already vulnerable cardiovascular milieu could lead to 
myocardial stunning and further activation of the neurohormonal cascade responsible for 
adverse electrical and ventricular remodeling. Further research is needed to explore 
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methods to decrease ventricular arrhythmia burden and to delineate appropriate ICD 
programming for effectively treating ventricular arrhythmias while minimizing the ICD 
shock burden to patients.  
Electrical storm is a critical cardiac condition which demands aggressive intervention. Initial 
antiarrhythmic therapies need to be followed by a careful and thorough evaluation of the 
entire cardiac status. With the current treatment armamentarium, immediate mortality can 
often be averted, but the accompanying high early mortality post-ES calls for aggressive 
substrate modification aiming at maximized CHF and arrhythmia management as well as 
reduction of the possible ischemic burden.7,11,12 Prophylactic measures such as pre-emptive 
VT substrate modification with ablation or medication hold promise but remain to be 
established in large series. 
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